- 作者：Elliot Lee? ; elliotdl@umich.edu ; Selwan Edward&Dagger ; ; Amit G. Singal§ ; ; Mariel S. Lavieri? ; Michael Volk&Dagger ;
- 关键词：HALT-C Trial ; Biomarker ; Surveillance ; Cancer Detection ; AUROC
- 刊名：Clinical Gastroenterology and Hepatology
- 出版年：2013
- 出版时间：April, 2013
- 年：2013
- 卷：11
- 期：4
- 页码：437-440
- 全文大小：505 K
Background & Aims
Current screening algorithms for hepatocellular carcinoma (HCC) view each testing interval independently, without considering prior test results. We investigated whether measurements of ¦Á-fetoprotein (AFP), over time, can be used to identify patients most likely to develop HCC.Methods
We performed a nested case-control study using data from subjects in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis trial; 82 patients with HCC were matched 1:3 to individuals without HCC (controls), using bootstrap methods to ensure similar follow-up times between groups. We assessed the independent association between development of HCC and the following: (1) most recent level of AFP, (2) standard deviation in level of AFP, and (3) rate of increase in AFP using a multiple logistic regression that included patient-specific risk factors such as age, platelet count, and smoking status.
Results
In bivariable analysis, all 3 AFP metrics were associated with HCC development; the most strongly associated was the standard deviation of AFP (odds ratio, 1.03 per unit increase in standard deviation; P < .001). Incorporating the standard deviation of AFP and rate of AFP increase, along with patient-specific risk factors, improved the prognostic accuracy to an area under the receiver-operating characteristic curve of 0.81, compared with 0.76 when only the most recent AFP level was used.
Conclusions
Patterns of AFP test results can more accurately identify patients with hepatitis C and advanced fibrosis or cirrhosis most likely to develop HCC, compared with most recent AFP test results.